Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot, Phase 2a, Randomized, Double-blind, Placebo-controlled, Cross-over Clinical Study to Evaluate Safety and Efficacy of Sublingual MTX101 for the Acute Treatment of Migraine Headaches in Adults

NCT06728553 is registered in ClinicalTrials.gov with Manistee Therapeutics as lead sponsor.

NCT NCT06728553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06728553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot, Phase 2a, Randomized, Double-blind, Placebo-controlled, Cross-over Clinical Study to Evaluate Safety and Efficacy of Sublingual MTX101 for the Acute Treatment of Migraine Headaches in Adults
Lead sponsor
Manistee Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
February 24, 2025
Completion date
July 28, 2025
Enrollment
78 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

migraine